Supported by grants from the German Research Foundation (MU4279/2-1 to PLM); Mexican National Council of Science and Technology (to AOB); Wellcome Trust (220558/Z/20/Z to ANW); National Eye Institute, National Institutes of Health (K23EY029246 to AYL); Lantham Vision Innovation Award (to AYL); and Research to Prevent Blindness (to AYL), in addition to support from the National Institute for Health Research Biomedical Research Centre based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology (to AT and CE) and the Special Trustees of Moorfields Eye Hospital (to UK Biobank Eye and Vision Consortium). The views expressed are those of the authors and not necessarily those of the National Health Service, National Institute for Health Research, Department of Health, or the U.S. Food and Drug Administration. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Disclosure: P.L. Müller, None; Y. Kihara, None; A. Olvera-Barrios, None; A.N. Warwick, None; C. Egan, Heidelberg Engineering (C, R), Novartis Pharmaceuticals (F); K.M. Williams, None; A.Y. Lee, Santen (F), U.S. Food and Drug Administration (R), Genentech (C, R), Gyroscope (R), Carl Zeiss Meditec (F), Topcon (F), Microsoft (R), Johnson & Johnson (C, R); A. Tufail, Allergan (C, R), Bayer (F, C, R), Kanghong (R), Heidelberg Engineering (C, R), Novartis (F, C, R), Roche/Genentech (C, R), Iveric Bio (C, R), Apellis (C, R), Thea (C, R)